<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>About Brintellix</title>

    <!-- bootstrap css -->
    <link rel="stylesheet" href="asset/css/bootstrap.min.css" />
    <!-- owl-carousel  -->
    <link rel="stylesheet" href="asset/css/owl.carousel.min.css" />
    <!-- main CSS -->
    <link rel="stylesheet" href="asset/css/main.css" />
</head>

<body>
    <!-- ========================= -->
    <!-- header section  -->
    <!-- ========================= -->
    <div class="header-top-cnt blue">
        <p>THIS SITE IS FOR UK HEALTHCARE PROFESSIONALS ONLY</p>
    </div>
    <header class="header">
        <nav class="navbar navbar-expand-lg navbar-light p-0">
            <div class="collapse navbar-collapse" id="navbarSupportedContent">
                <ul class="navbar-nav align-items-center me-auto">
                    <li class="nav-item">
                        <a href="home.html" class="header-link">
                            <img src="asset/image/Home-icon.png" alt="" />
                            HOME</a>
                    </li>
                    <li class="nav-item">
                        <a href="patient_experience.html" class="header-link">
                            <img src="asset/image/Patient-icon.png" alt="" />
                            patient experience</a>
                    </li>
                    <li class="nav-item active">
                        <a href="about_brintellix.html" class="header-link">
                            <img src="asset/image/AB_ico.png" alt="" />
                            ABOUT BRINTELLIX</a>
                    </li>
                    <li class="nav-item">
                        <a href="#" class="header-link">
                            <img src="asset/image/AE_icon.png" alt="" />
                            report an adverse Event</a>
                    </li>
                    <li class="nav-item">
                        <a href="#" class="header-link">
                            <img src="asset/image/PI_icon.png" alt="" />
                            prescribing information</a>
                    </li>
                </ul>
            </div>
            
            <a class="navbar-brand logo" href="#"><img src="asset/image/logo.png" alt="" /></a>
            <button id="nav-burger">
                <span></span>
                <span></span>
                <span></span>
                <span></span>
            </button>
        </nav>
        <hr class="divider" />
    </header>
    <!-- ========================= -->
    <!-- banner section  -->
    <!-- ========================= -->
    <section class="banner about-sec  ">
        <div class="container">
            <div class="banner-wraper">
                <p class="major">
                    Brintellix (vortioxetine) is indicated for the treatment of major
                    depressive episodes in adults.1 <br />
                    Prescribing information can be accessed via the tab at the top of
                    this page.
                </p>
                <div class="row flex-sm-column-reverse flex-column-reverse flex-md-row">
                    <div class="col-lg-6 col-md-6 col-sm-12 d-flex justify-content-center">
                        <div class="about-cnt d-flex align-items-baseline justify-content-center flex-column">
                            <figure class="feel-sec-bg ">
                                <img src="asset/image/about-img3.png" alt="">
                            </figure>
                            <div class="re-engage-cnt">
                                <h1>About Brintellix (vortioxetine) </h1>
                                <span class="font-size-20-blue">Re-engage with life2-5</span>
                            </div>

                        </div>
                    </div>
                    <div class="col-lg-6 col-md-6 col-sm-12">
                        <figure class="banner-left-img about-left-img">
                            <img src="asset/image/about-banner-img.png" alt="" />
                        </figure>
                    </div>

                </div>
            </div>
        </div>
        <span class="used">Fictional patients used for illustrative purposes.</span>
    </section>
    <!-- ========================= -->
    <!-- depression section  -->
    <!-- ========================= -->
    <section class="depression cmn-banner">
        <div class="container2">
            <h3>Depression is a multi-faceted disorder⁶ </h3>
            <figure class="depresion-img"><img src="asset/image/depression-img1.png" alt=""></figure>
        </div>
    </section>
    <!-- ========================= -->
    <!-- depression2 section  -->
    <!-- ========================= -->
    <section class="depression">
        <div class="container2">
            <h3>Multiple pathways are thought to be responsible <br> for the different symptoms of depression⁹ ¹⁰ </h3>
            <figure class="depresion-img depresion-img2"><img src="asset/image/depression-img2.png" alt=""></figure>
        </div>
    </section>
    <!-- ========================= -->
    <!-- depression3 section  -->
    <!-- ========================= -->
    <section class="depression">
        <div class="container2">
            <div class="multimodal-cnt">
                <h3>Brintellix exhibits a multimodal pharmacological profile¹</h3>
                <ul class="both">
                    <li>
                        <span class="week">Brintellix is an antidepressant with a multimodal mechanism of action that
                            combines modulation of 5-HT receptor activity with SERT inhibition¹¹</span>
                    </li>
                </ul>
            </div>
            <figure class="depresion-img depresion-img3 pt-0"><img src="asset/image/depression-img3.png" alt="">
            </figure>
            <div class="depression-btm-cnt">
                <p class="font-size-14">Nonclinical data indicate that vortioxetine modulates neurotransmission in
                    several systems, including
                    predominantly the serotonin but probably also the norepinephrine, dopamine, histamine,
                    acetylcholine, GABA and glutamate systems. However, the precise contribution of the individual
                    targets to the observed pharmacodynamic profile remains unclear and caution should be applied when
                    extrapolating animal data directly to man.¹</p>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- warnnings section  -->
    <!-- ========================= -->
    <section class="warnings">
        <div class="container">
            <div class="warnings-warp">
                <p class="pb-3">
                    Brintellix may help give your patients diagnosed with major depressive disorder (MDD) the life they
                    deserve.²³⁵
                </p>
                <p class="pb-0">Find out more about Brintellix efficacy in the Patient experience section </p>
                <a href="patient_experience.html" class="about-btn patient-btn">Patient experience</a>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- tab section  -->
    <!-- ========================= -->
    <section class="tab-sec">
        <div class="container3">
            <div class="tab-sec-wrap">
                <ul class="tab_class" id="tabz">
                    <li><a class="active" target="tab1">NICE / SMC Guidelines and recommendations</a></li>
                    <li><a target="tab2">Tolerability</a></li>
                    <li><a target="tab3">Dosing</a></li>
                    <li><a target="tab4">Contraindications and drug interactions</a></li>
                    <li><a target="tab5">switching</a></li>
                    <li><a target="tab6">Special warnings and precautions</a></li>
                </ul>
                <div class="tab_body">
                    <!-- first tab body  -->
                    <div class="tab1_body activetab" id="tab1">
                        <h3>NICE and SMC Guidelines and recommendations</h3>
                        <div class="guideline-cnt">
                            <h4>National Institute for Health and Care Excellence (NICE)*¹²</h4>
                            <ul class="both">
                                <li>
                                    <span class="week">Brintellix is recommended by the NICE Guidelines TA367 as an
                                        option for treating major depressive episodes in adults whose condition has
                                        responded inadequately to two antidepressants within the current episode*¹²
                                    </span>
                                </li>
                                <li>
                                    <span class="week">People whose treatment with Brintellix is not recommended in this
                                        NICE guidance, but was started within the NHS before this guidance was
                                        published, should be able to continue treatment until they and their NHS
                                        clinician consider it appropriate to stop¹²</span>
                                </li>
                            </ul>
                        </div>
                        <div class="guideline-cnt">
                            <h4>Scottish Medicines Consortium (SMC)¹³</h4>
                            <ul class="both">
                                <li>
                                    <span class="week">The SMC has accepted Brintellix for restricted use in the
                                        treatment of major depressive episodes in adults who have experienced an
                                        inadequate response** to two or more previous antidepressants¹³
                                    </span>
                                </li>
                            </ul>
                            <span class="font-size-14 nice">*NICE guidance is also valid in Wales - When a NICE technology appraisal recommends the use of a drug or
                                <br>
                                treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 3 months of the guidance being published.¹² ¹⁴
                            </span>
                            <span class="font-size-14 nice pt-0">**Either due to lack of adequate efficacy and/or safety concerns/intolerability13</span>
                        </div>
                    </div>
                    <!-- second tab body  -->
                    <div class="tab1_body" id="tab2">
                        <h3>Brintellix: a generally well-tolerated option for your adult patients diagnosed with
                            MDD¹ ¹⁵ ¹⁶</h3>
                        <div class="row row-cols-6 general">
                            <div class="col-lg-6 col-sm-12 col-12">
                                <div class="exhibit-cnt">
                                    <figure class="exhibit-cnt-left"><img src="asset/image/exhibit-img1.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right">
                                        <h4>Brintellix exhibits a low withdrawal rate due to tolerability issues in
                                            short-term studies vs. placebo¹⁵</h4>
                                        <span class="font-size-14">Findings based on an analysis designed to assess the
                                            tolerability and
                                            safety of Brintellix in 11 randomised, double-blind, placebo-controlled
                                            short-term studies in depression and five long-term studies¹⁵</span>
                                    </div>
                                </div>
                            </div>
                            <div class="col-lg-6 col-sm-12 col-12">
                                <div class="exhibit-cnt">
                                    <figure class="exhibit-cnt-left"><img class="exhibit-img2"
                                            src="asset/image/exhibit-img2.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right">
                                        <h4>Nausea with Brintellix is usually mild to moderate and transient¹ ¹⁵</h4>
                                        <span class="font-size-14">The most common adverse reaction with Brintellix is
                                            nausea. Nausea with Brintellix is usually mild to moderate, transient, and
                                            does not generally lead to treatment discontinuation,¹⁵</span>
                                        <span class="font-size-14 pt-3">Gastrointestinal adverse reactions, such as
                                            nausea, occurred more
                                            frequently in women than men.¹</span>
                                    </div>
                                </div>
                            </div>
                            <div class="col-lg-6 col-sm-12 col-12 pdt-general">
                                <div class="exhibit-cnt">
                                    <figure class="exhibit-cnt-left"><img class="exhibit-img3"
                                            src="asset/image/exhibit-img3.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right">
                                        <h4>Brintellix showed no clinically meaningful effects on hepatic, renal, and
                                            cardiac function¹ ¹⁵ ¹⁷</h4>

                                    </div>
                                </div>
                            </div>
                            <div class="col-lg-6  col-sm-12 col-12 pdt-general">
                                <div class="exhibit-cnt">
                                    <figure class="exhibit-cnt-left"><img class="exhibit-img2"
                                            src="asset/image/exhibit-img4.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right">
                                        <h4>Minimal effects on body weight relative to placebo1 ¹ ¹⁵ </h4>
                                        <span class="font-size-14">Brintellix is associated with a mean weight increase
                                            of < 1 kg in patients treated with Brintellix for up to 12 months ¹ ¹⁵
                                                </span>
                                                <span class="font-size-14 pt-3">From an analysis designed to assess the
                                                    tolerability and safety of Brintellix in 11 randomised,
                                                    double-blind, placebo-controlled short-term studies in depression
                                                    and five long-term studies. 10 of the short-term studies included
                                                    participants aged 18-75, and one included participants aged over
                                                    65¹</span>
                                    </div>
                                </div>
                            </div>
                            <div class="col-lg-6 col-sm-12 col-12 pdt-general">
                                <div class="exhibit-cnt">
                                    <figure class="exhibit-cnt-left"><img class="exhibit-img2"
                                            src="asset/image/exhibit-img5.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right">
                                        <h4>Low rate of patient-reported sexual dysfunction
                                            at 5-15 mg*¹ ¹⁵</h4>
                                        <span class="font-size-14">Patient-reported sexual dysfunction with Brintellix
                                            was low, and similar to that in the placebo group during short-and long-term
                                            treatment (1.6-1.8% vs 1.0%)¹⁵</span>
                                        <span class="font-size-14 pt-3">*Brintellix 15 mg is not available for use in
                                            the UK. The 20 mg dose of Brintellix was associated with an increase in
                                            sexual dysfunction compared to placebo.1 Sexual dysfunction was assessed
                                            using the Arizona Sexual Experience Scale (ASEX)</span>
                                    </div>
                                </div>
                            </div>
                            <div class="col-lg-6 col-sm-12 col-12 pdt-general">
                                <div class="exhibit-cnt">
                                    <figure class="exhibit-cnt-left"><img class="exhibit-img2"
                                            src="asset/image/exhibit-img6.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right">
                                        <h4>Brintellix does not increase the incidence of insomnia or somnolence
                                            relative to placebo†¹ ¹⁵</h4>
                                        <span class="font-size-14">†In a pooled analysis of 11 short-term (6/8 week)
                                            randomised, double-blind, placebo-controlled clinical trials, Brintellix did
                                            not increase the incidence of insomnia or somnolence relative to
                                            placebo.1,15 There have been reports of insomnia during the post-marketing
                                            period¹</span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="summary">
                            <span class="font-size-20">For full details please refer to the Brintellix Summary of
                                Product Characteristics1 </span>
                        </div>
                        <span class="font-size-14 disorder">MDD, major depressive disorder.</span>
                    </div>
                    <!-- third tab body  -->
                    <div class="tab1_body" id="tab3">
                        <h3>Brintellix Dosing: Prescribing Brintellix for your patients </h3>
                        <div class="row general">
                            <div class="col-lg-6   col-md-12">
                                <div class="exhibit-cnt">
                                    <figure class="exhibit-cnt-left exhibit-cnt-left2"><img
                                            src="asset/image/exhibit-img1.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right exhibit-cnt-right2">
                                        <h4>Brintellix Dosing:¹</h4>
                                        <ul class="both">
                                            <li>
                                                <span class="week">The starting and recommended dose for adult patients
                                                    < 65 years is Brintellix 10 mg once daily</span>
                                            </li>
                                            <li>
                                                <span class="week">Can be increased or decreased between 5 mg and 20 mg
                                                    daily, depending on the individual patient‘s response</span>
                                            </li>
                                            <li>
                                                <span class="week">
                                                    After the depressive symptoms resolve, treatment for at least 6
                                                    months is recommended for consolidation of the antidepressive
                                                    response</span>
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <figure class="exhibit-cnt-left exhibit-cnt-left2"><img class="exhibit-img2"
                                            src="asset/image/exhibit-img2.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right exhibit-cnt-right2">
                                        <h4>Treatment discontinuation:¹</h4>
                                        <ul class="both">
                                            <li>
                                                <span class="week">Can be stopped abruptly without the need for gradual
                                                    dose reduction</span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <figure class="exhibit-cnt-left exhibit-cnt-left2"><img class="exhibit-img2"
                                            src="asset/image/exhibit-img2.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right exhibit-cnt-right2">
                                        <h4>Elderly patients:¹</h4>
                                        <ul class="both">
                                            <li>
                                                <span class="week">Patients aged ≥65 should always start on 5 mg once
                                                    daily</span>
                                            </li>
                                            <li>
                                                <span class="week">Caution is advised when treating patients ≥65 years
                                                    old with doses higher than 10 mg once daily for which data are
                                                    limited</span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <figure class="exhibit-cnt-left exhibit-cnt-left2"><img class="exhibit-img2"
                                            src="asset/image/exhibit-img2.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right exhibit-cnt-right2">
                                        <h4>Renal or hepatic impairment:¹</h4>
                                        <ul class="both">
                                            <li>
                                                <span class="week">No dose adjustment is needed based on renal or
                                                    hepatic function</span>
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                                <div class="summary summary2">
                                    <span class="font-size-20">For full details please refer to the Brintellix Summary
                                        of Product Characteristics¹ </span>
                                </div>
                            </div>
                            <div class="col-lg-6 col-md-12 pt-lg-0 pt-md-4 pt-sm-3 pt-3">
                                <div class="taking-cnt">
                                    <span class="font-size-20">Taking Brintellix:1</span>
                                    <ul class="both">
                                        <li>
                                            <span class="week">Can be taken with or without food at any time of the
                                                day</span>
                                        </li>
                                    </ul>
                                    <figure class="med-img up-down">
                                        <img src="asset/image/about-img4.png" alt="">
                                    </figure>
                                </div>
                            </div>

                        </div>
                    </div>
                    <!-- forth tab body  -->
                    <div class="tab1_body" id="tab4">
                        <h3>Brintellix contraindications and drug interactions¹</h3>
                        <h4>Key considerations when combining Brintellix with other medications:¹</h4>
                        <div class="row general  ">
                            <div class="col-lg-7">
                                <div class="exhibit-cnt">
                                    <figure class="exhibit-cnt-left exhibit-cnt-left2"><img class="exhibit-img2"
                                            src="asset/image/cross.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right exhibit-cnt-right2">
                                        <span class="font-size-20">Contraindications¹</span>
                                        <ul class="both">
                                            <li>
                                                <span class="week">Hypersensitivity to active substance or excipients
                                                    (please refer to the Summary of Product Characteristics for full
                                                    list of excipients) </span>
                                            </li>
                                            <li>
                                                <span class="week">Concomitant use with non-selective monoamine oxidase
                                                    inhibitors (MAOIs) or selective monoamine oxidase-A (MAO-A)
                                                    inhibitors (moclobemide) </span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <figure class="exhibit-cnt-left exhibit-cnt-left2 violet"><img class="exhibit-img4"
                                            src="asset/image/exclamation.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right exhibit-cnt-right2">
                                        <span class="font-size-20">Monitor for serotonin syndrome:¹</span>
                                        <ul class="both">
                                            <li>
                                                <span class="week">Irreversible selective monoamine oxidase-B (MAO-B)
                                                    inhibitors (rasagiline, selegiline) –administer with caution </span>
                                            </li>
                                            <li>
                                                <span class="week">Drugs with a serotonergic effect (opioids (including
                                                    tramadol); triptans (including sumatriptan) </span>
                                            </li>
                                            <li>
                                                <span class="week">St John’s wort - concomitant use of antidepressants
                                                    with serotonergic effect and St. John’s wort (Hypericum perforatum)
                                                    may result in a higher incidence of adverse reactions including
                                                    serotonin syndrome </span>
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <figure class="exhibit-cnt-left exhibit-cnt-left2 bg-trans">
                                    </figure>
                                    <div class="exhibit-cnt-right exhibit-cnt-right2">
                                        <span class="font-size-20">Proceed with caution:¹</span>
                                        <ul class="both">
                                            <li>
                                                <span class="week">Medicinal products lowering the seizure threshold
                                                    [e.g. antidepressants (tricyclics, SSRIs, SNRIs), neuroleptics
                                                    (phenothiazines, thioxanthenes and butyrophenones), mefloquine,
                                                    bupropion, tramadol]</span>
                                            </li>
                                            <li>
                                                <span class="week">ECT (electroconvulsive therapy) </span>
                                            </li>
                                            <li>
                                                <span class="week">CYP2D6 inhibitors (bupropion, quinidine, fluoxetine,
                                                    paroxetine) – consider a dose adjustment</span>
                                            </li>
                                            <li>
                                                <span class="week">Broad CYP450 inducers (rifampicin, carbamazepine,
                                                    phenytoin) – consider a dose adjustment</span>
                                            </li>
                                            <li>
                                                <span class="week">Anticoagulants and medicinal products known to affect
                                                    platelet function</span>
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <figure class="exhibit-cnt-left exhibit-cnt-left2 bg-trans">
                                    </figure>
                                    <div class="exhibit-cnt-right   min-height">
                                        <span class="font-size-20">No known effects with:¹</span>
                                        <ul class="both">
                                            <li>
                                                <span class="week">Diazepam </span>
                                            </li>
                                            <li>
                                                <span class="week">Oral contraceptives </span>
                                            </li>

                                        </ul>

                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <figure class="exhibit-cnt-left exhibit-cnt-left2  violet mt-0">
                                        <img class="exhibit-img4" src="asset/image/exclamation.png" alt="">
                                    </figure>
                                    <div class="exhibit-cnt-right min-height">

                                        <p class="given font-size-16">Given that subjects with renal or hepatic
                                            impairment are vulnerable and given
                                            that the data on the use of Brintellix in these subpopulations are limited,
                                            caution should be exercised when treating these patients.</p>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                    <!-- fifth tab body  -->
                    <div class="tab1_body" id="tab5">
                        <h3>Brintellix: Practical guidance on switching¹ ¹⁸</h3>
                        <h4>Switching to Brintellix from other antidepressants:¹⁸</h4>
                        <div class="row general  general2">
                            <div class="col-lg-6 col-md-12">
                                <div class="exhibit-cnt">
                                    <div class="exhibit-cnt-right min-height">
                                        <span class="font-size-20">SSRIs and SNRIs¹⁸</span>
                                        <ul class="both">
                                            <li>
                                                <span class="week">Direct switch possible</span>
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <div class="exhibit-cnt-right min-height">
                                        <span class="font-size-20">Mirtazapine¹⁸</span>
                                        <ul class="both">
                                            <li>
                                                <span class="week">Cross taper cautiously (usually over 1 to 2
                                                    weeks)</span>
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">

                                    <div class="exhibit-cnt-right min-height">
                                        <span class="font-size-20">Tricyclic antidepressants (TCAs)¹⁸</span>
                                        <ul class="both">
                                            <li>
                                                <span class="week">Halve TCA dose, add Brintellix and then withdraw the
                                                    TCA slowly </span>
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">

                                    <div class="exhibit-cnt-right min-height">
                                        <span class="font-size-20">Monoamine oxidase inhibitors (MAOIs)¹⁸</span>
                                        <ul class="both">
                                            <li>
                                                <span class="week">Taper and stop MAOI</span>
                                            </li>
                                            <li>
                                                <span class="week">Wait 14 days before initiating Brintellix </span>
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <ul class="guide-cnt">
                                        <li>
                                            <span class="font-size-16-br">Guidance based on general recommendations from
                                                switching between classes in the Maudsley Prescribing Guidelines on
                                                Psychiatry.18 These are third party recommendations and prescribers
                                                should use them in conjunction with their own clinical judgement.
                                            </span>
                                        </li>
                                        <li>
                                            <span class="font-size-16-br">The advice given should be treated with
                                                caution
                                                and patients should be very carefully monitored when ‘switching’ as
                                                stated in the Maudsley Guidelines.18
                                            </span>
                                        </li>
                                        <li>
                                            <span class="font-size-16-br">It is very important that prescribers consult
                                                the
                                                Summary of Product Characteristics for any medication they are
                                                considering switching from prior to making the switch.
                                            </span>
                                        </li>
                                        <li>
                                            <span class="font-size-14">MAOI, monoamine oxidase inhibitor; MAO-A,
                                                monoamine oxidase A; MAO-B, monamine oxidase B; SNRI,
                                                serotonin-noradrenaline reuptake inhibitor; SSRI, selective serotonin
                                                reuptake inhibitor; TCA, tricyclic antidepressant.
                                            </span>
                                        </li>
                                    </ul>

                                </div>

                            </div>
                        </div>
                    </div>
                    <!-- sixth tab body  -->
                    <div class="tab1_body" id="tab6">
                        <h3>Brintellix special warnings and precautions¹</h3>

                        <div class="row general  general2">
                            <div class="col-xxl-6 col-lg-8 col-md-12 col-sm-12 col-12">
                                <div class="exhibit-cnt">
                                    <div class="exhibit-cnt-right min-height">
                                        <h4 class="pt-0"> Use in paediatric population¹</h4>
                                        <ul class="guide-cnt">
                                            <li>
                                                <span class="font-size-16-br">Brintellix is not recommended for the
                                                    treatment of depression in children aged 7 to 11 years since the
                                                    safety and efficacy of Brintellix have not been established in this
                                                    age group. Brintellix should not be used in adolescents aged 12 to
                                                    17 years with major depressive disorder (MDD) because efficacy has
                                                    not been demonstrated (see section 5.1 of SmPC). In general, the
                                                    adverse reaction profile of Brintellix in adolescents was similar to
                                                    that seen for adults except for higher incidences reported in
                                                    adolescents than in adults for abdominal pain-related events and
                                                    suicidal ideation (see section 4.8 and 5.1 of SmPC). In clinical
                                                    studies in children and adolescents treated with antidepressants,
                                                    suicide-related behaviour (suicide attempt and suicidal thoughts)
                                                    and hostility (predominantly aggression, oppositional behaviour,
                                                    anger) were more frequently observed than in those treated with
                                                    placebo.
                                                </span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <div class="exhibit-cnt-right min-height">
                                        <h4 class="pt-0">Suicide/suicidal thoughts or clinical worsening¹</h4>
                                        <ul class="guide-cnt">
                                            <li>
                                                <span class="font-size-16-br">Depression is associated with an increased
                                                    risk of suicidal thoughts, self-harm and suicide (suicide-related
                                                    events). This risk persists until significant remission occurs. As
                                                    improvement may not occur during the first few weeks or more of
                                                    treatment, patients should be closely monitored until such
                                                    improvement occurs. It is general clinical experience that the risk
                                                    of suicide may increase in the early stages of recovery.
                                                </span>
                                            </li>
                                            <li>
                                                <span class="font-size-16-br">Patients with a history of suicide-related
                                                    events or those exhibiting a significant degree of suicidal ideation
                                                    prior to commencement of treatment are known to be at greater risk
                                                    of suicidal thoughts or suicide attempts, and should receive careful
                                                    monitoring during treatment. A meta-analysis of placebo-controlled
                                                    clinical studies of antidepressants in adult patients with
                                                    psychiatric disorders showed an increased risk of suicidal behaviour
                                                    with antidepressants compared to placebo, in patients less than 25
                                                    years old.

                                                </span>
                                            </li>
                                            <li>
                                                <span class="font-size-16-br">Close supervision of patients and in
                                                    particular those at high risk should accompany treatment especially
                                                    in early treatment and following dose changes. Patients (and
                                                    caregivers of patients) should be alerted to the need to monitor for
                                                    any clinical worsening, suicidal behaviour or thoughts and unusual
                                                    changes in behaviour and to seek medical advice immediately if these
                                                    symptoms present.
                                                </span>
                                            </li>
                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <div class="exhibit-cnt-right min-height">
                                        <h4 class="pt-0">Seizures¹</h4>
                                        <ul class="guide-cnt">
                                            <li>
                                                <span class="font-size-16-br">Seizures are a potential risk with
                                                    antidepressants. Therefore, Brintellix should be introduced
                                                    cautiously in patients who have a history of seizures or in patients
                                                    with unstable epilepsy (see section 4.5 of SmPC). Treatment should
                                                    be discontinued in any patient who develops seizures or for whom
                                                    there is an increase in seizure frequency.
                                                </span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <div class="exhibit-cnt-right min-height">
                                        <h4 class="pt-0">Serotonin Syndrome (SS) or Neuroleptic Malignant Syndrome
                                            (NMS)¹</h4>
                                        <ul class="guide-cnt">
                                            <li>
                                                <span class="font-size-16-br">Serotonin Syndrome (SS) or Neuroleptic
                                                    Malignant Syndrome (NMS), potentially life-threatening conditions,
                                                    may occur with Brintellix. The risk of SS or NMS is increased with
                                                    concomitant use of serotonergic-active substances (including opioids
                                                    and triptans), medicinal products that impair the metabolism of
                                                    serotonin (including MAOIs), antipsychotics, and other dopamine
                                                    antagonists. Patients should be monitored for the emergence of signs
                                                    and symptoms of SS or NMS (see sections 4.3 and 4.5). of SmPC).
                                                </span>
                                            </li>
                                            <li>
                                                <span class="font-size-16-br">Serotonin Syndrome symptoms include mental
                                                    status changes (e.g., agitation, hallucinations, coma), autonomic
                                                    instability (e.g., tachycardia, labile blood pressure,
                                                    hyperthermia), neuromuscular aberrations (e.g., hyperreflexia,
                                                    uncoordination) and/or gastrointestinal symptoms (e.g., nausea,
                                                    vomiting, diarrhoea). If this occurs, treatment with Brintellix
                                                    should be discontinued immediately and symptomatic treatment should
                                                    be initiated.
                                                </span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <div class="exhibit-cnt-right min-height">
                                        <h4 class="pt-0">Mania/hypomania¹</h4>
                                        <ul class="guide-cnt">
                                            <li>
                                                <span class="font-size-16-br">Brintellix should be used with caution in
                                                    patients with a history of mania/hypomania and should be
                                                    discontinued in any patient entering a manic phase.
                                                </span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <div class="exhibit-cnt-right min-height">
                                        <h4 class="pt-0">Aggression/agitation¹</h4>
                                        <ul class="guide-cnt">
                                            <li>
                                                <span class="font-size-16-br">Patients treated with antidepressants,
                                                    including Brintellix, may also experience feelings of aggression,
                                                    anger, agitation and irritability. Patient’s condition and disease
                                                    status should be closely monitored. Patients (and caregivers of
                                                    patients) should be alerted to seek medical advice, if
                                                    aggressive/agitated behaviour emerges or aggravates.
                                                </span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <div class="exhibit-cnt-right min-height">
                                        <h4 class="pt-0">Haemorrhage¹</h4>
                                        <ul class="guide-cnt">
                                            <li>
                                                <span class="font-size-16-br">Bleeding abnormalities, such as
                                                    ecchymoses, purpura and other haemorrhagic events, such as
                                                    gastrointestinal or gynaecological bleeding, have been reported
                                                    rarely with the use of antidepressants with serotonergic effect,
                                                    including Brintellix. SSRIs/SNRIs may increase the risk of
                                                    postpartum haemorrhage, and this risk could potentially apply also
                                                    to Brintellix (see section 4.6 of SmPC). Caution is advised in
                                                    patients taking anticoagulants and/or medicinal products known to
                                                    affect platelet function [e.g., atypical antipsychotics and
                                                    phenothiazines, most tricyclic antidepressants, non-steroidal
                                                    anti-inflammatory drugs (NSAIDs), acetylsalicylic acid (ASA)] (see
                                                    section 4.5 of SmPC) and in patients with known bleeding
                                                    tendencies/disorders.
                                                </span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <div class="exhibit-cnt-right min-height">
                                        <h4 class="pt-0">Hyponatraemia¹</h4>
                                        <ul class="guide-cnt">
                                            <li>
                                                <span class="font-size-16-br">Hyponatraemia, probably due to
                                                    inappropriate antidiuretic hormone secretion (SIADH), has been
                                                    reported rarely with the use of antidepressants with serotonergic
                                                    effect (SSRIs, SNRIs). Caution should be exercised in patients at
                                                    risk, such as the elderly, patients with cirrhosis of the liver or
                                                    patients concomitantly treated with medicinal products known to
                                                    cause hyponatraemia. Discontinuation of Brintellix should be
                                                    considered in patients with symptomatic hyponatraemia and
                                                    appropriate medical intervention should be instituted.
                                                </span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <div class="exhibit-cnt-right min-height">
                                        <h4 class="pt-0">Glaucoma¹</h4>
                                        <ul class="guide-cnt">
                                            <li>
                                                <span class="font-size-16-br">Mydriasis has been reported in association
                                                    with use of antidepressants, including Brintellix. This mydriatic
                                                    effect has the potential to narrow the eye angle resulting in
                                                    increased intraocular pressure and angle-closure glaucoma. Caution
                                                    is advised when prescribing Brintellix to patients with increased
                                                    intraocular pressure, or those at risk of acute narrow-angle
                                                    glaucoma.
                                                </span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <div class="exhibit-cnt-right min-height">
                                        <h4 class="pt-0">Elderly¹</h4>
                                        <ul class="guide-cnt">
                                            <li>
                                                <span class="font-size-16-br">Data on the use of Brintellix in elderly
                                                    patients with major depressive episodes are limited. Therefore,
                                                    caution should be exercised when treating patients ≥ 65 years of age
                                                    with doses higher than 10 mg Brintellix once daily (see sections
                                                    4.2, 4.8 and 5.2 of SmPC).
                                                </span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                                <div class="exhibit-cnt exhibit-cnt-2">
                                    <div class="exhibit-cnt-right min-height">
                                        <h4 class="pt-0">Renal or hepatic impairment¹</h4>
                                        <ul class="guide-cnt">
                                            <li>
                                                <span class="font-size-16-br">Given that subjects with renal or hepatic
                                                    impairment are vulnerable and given that the data on the use of
                                                    Brintellix in these subpopulations are limited, caution should be
                                                    exercised when treating these patients. (See section 4.2 and 5.2 of
                                                    SmPC).
                                                </span>
                                            </li>

                                        </ul>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- poolded section  -->
    <!-- ========================= -->
    <section class="pooled">
        <div class="container3">
            <div class="pooled-wrap">
                <div class="row">
                    <div class="col-lg-6">
                        <div class="pooled-cnt">
                            <h4>Brintellix has a low rate of treatment-emergent adverse events¹ ¹⁵ </h4>
                            <p>The most common adverse reaction with Brintellix was nausea (very common (≥1/10)¹
                            </p>
                            <p class="pt-3">Other common adverse events (≥1/100 to < 1/10) included:¹</p>
                                    <ul class="both">
                                        <li>
                                            <span class="week">Abnormal dreams</span>
                                        </li>
                                        <li>
                                            <span class="week">Dizziness</span>
                                        </li>
                                        <li>
                                            <span class="week">
                                                Diarrhoea, constipation, vomiting</span>
                                        </li>
                                        <li>
                                            <span class="week">
                                                Pruritus, including pruritus generalised, hyperhidrosis</span>
                                        </li>
                                    </ul>
                                    <p class="refer">Please refer to the Summary of Product Characteristics for a full
                                        list of adverse
                                        reactions (based on information from clinical trials and post-marketing
                                        experience)¹</p>
                        </div>
                    </div>
                    <div class="col-lg-6">
                        <div class="pooled-cnt">
                            <h4>In a pooled analysis of 11 short-term (6/8 week) randomised, double-blind,
                                placebo-controlled clinical trials:¹⁵ </h4>
                            <p>Treatment-emergent adverse events (TEAEs) of ≥5% incidence in any treatment group¹⁵
                            </p>

                            <div class="table-cnt table-responsive">
                                <table class="table">
                                    <thead>
                                        <tr>
                                            <th scope="col">Preferred term</th>
                                            <th scope="col">Placebo
                                                (n=1817)
                                            </th>
                                            <th scope="col">Brintellix 5 mg (n=1013)</th>
                                            <th scope="col">Brintellix 10 mg (n=894)</th>
                                            <th scope="col">Brintellix 15 mg (n=449)</th>
                                            <th scope="col">Brintellix 20 mg (n=662)</th>
                                            <th scope="col">Venlafaxine 225 mg (n=113)</th>
                                            <th scope="col">Duloxetine 60 mg (n=753)</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <th scope="row">% patients with TEAEs</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Nausea</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Headache</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Dry mouth</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Dizziness</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Diarrhoea</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Vomiting</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Insomnia</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Constipation</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Somnolence</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Fatigue</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Decreased appetite</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Sexual dysfunction</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                        <tr>
                                            <th scope="row">Hyperhidrosis</th>
                                            <td>58</td>
                                            <td>65</td>
                                            <td>61</td>
                                            <td>69</td>
                                            <td>65</td>
                                            <td>75</td>
                                            <td>76</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                            <p class="refer">Duloxetine and venlafaxine were included as active references for study
                                validation only¹⁵
                            </p>
                            <p class="refer">TEAEs above the orange line occur with a frequency ≥5% for Brintellix¹⁵
                            </p>
                            <p class="refer pt-3">Brintellix 15 mg is not available for use in the UK.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- reference   section  -->
    <!-- ========================= -->
    <section class="reference light-white2">
        <div class="container">
            <div class="reference-wrap">
                <div class="adverse-blk">
                    <span class="events">Adverse events should be reported.
                    </span>
                    <p>Reporting forms and information can be found at <a href="#"
                            class="yellowcard">www.mhra.gov.uk/yellowcard</a> Adverse events should
                        also be reported to Lundbeck Limited, Medical Information, on: <a class="mobile-number"
                            href="tel:01908 638972">01908 638972</a> or Email:
                        <a href="mailto:SafetyLuUnitedKingdom@lundbeck.com" class="yellowcard">
                            SafetyLuUnitedKingdom@lundbeck.com</a>

                    </p>

                </div>
                <div class="reference-cnt">
                    <span class="ref-head">References</span>
                    <ul class="reference-list reference-list2">
                        <li><span>Lundbeck. Brintellix. Summary of Product Characteristics GB and NI.</span></li>
                        <li><span>Chokka P et al. CNS Spectrums. 2019 Dec;24(6):616-27. </span></li>
                        <li><span>Cao B et al. Frontiers in psychiatry. 2019 Jan 31;10:17. </span></li>
                        <li><span>Baune BT et al. Int J Neuropsychopharm. 2018 Feb;21(2):97-107. </span></li>
                        <li><span>Fagiolini A et al. J Affect Disord. 2021 Mar 15;283:472-9. </span></li>
                        <li><span>American Psychiatric Association. Diagnostic and Statistical Manual of Mental
                                Disorders. Fifth Edition, Text Revision (DSM-5-TR). 2022.
                                https://doi.org/10.1176/appi.books.9780890425787. </span></li>
                        <li><span>NHS. Symptoms – clinical depression. Available at:
                                www.nhs.uk/mental-health/conditions/clinical-depression/symptoms/ Last accessed June
                                2023. </span></li>
                        <li><span>Marazziti D et al. Eur J Pharmacol 2010 Jul;626(1):83–86.</span></li>
                        <li><span>Saltiel PF, Silvershein DI. Neuropsychiatr Dis Treat. 2015 Mar 31;11:875-888. </span>
                        </li>
                        <li><span>Nutt DJ. J Clin psychiatry. 2008 Jan 1;69(Suppl E1):4-7. </span></li>
                        <li><span>Sanchez C et al. Pharmacology & therapeutics. 2015 Jan 1;145:43-57. </span></li>
                        <li><span>National Institute For Health And Care Excellence. TA367. November 2015. </span></li>
                        <li><span>Scottish Medicines Consortium. SMC No. (1158/16). July 2016. </span></li>
                        <li><span>All Wales Medicines Strategy Group. 1199 SOA. April 2014. </span></li>
                        <li><span>Baldwin DS et al. J Psychopharmacol 2016;30:242–252.</span></li>
                        <li><span>Citrome L. J Affect Disord 2016;196:225–233.</span></li>
                        <li><span>Wang Y et al. Clin Pharmacol Drug Dev 2013;2:298–309. </span></li>
                        <li><span>The Maudsley prescribing guidelines in psychiatry. 14th ed. Wiley Blackwell,
                                2021;335–341.</span></li>
                    </ul>
                    <span class="ref-head">UK-BRIN-1278 | June 2023</span>
                </div>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- footer   section  -->
    <!-- ========================= -->
    <footer>
        <hr class="footer-divider">
        <div class="container">
            <div class="row">
                <div class="footer-log d-flex">
                    <a href="#" class="footer-logo"><img src="asset/image/footer-logo.png" alt=""></a>
                </div>
                <div class="location">
                    <p>Lundbeck Limited <br>
                        Iveco House, Station Road <br>
                        Watford, Hertfordshire <br>
                        WD17 1ET <br>
                        United Kingdom</p>
                    <span class="ref-head">UK-BRIN-1360 | June 2023</span>
                </div>
                <div class="contact">
                    <span class="ref-head">Contact us </span>
                    <a class="mail-link" href="tel:+44 1908 649 966">+44 1908 649 966</a>
                    <a href="mailto:united_kingdom@lundbeck.com" class="mail-link">united_kingdom@lundbeck.com</a>
                </div>
                <div class="footer-link-cnt">
                    <span class="ref-head">Links</span>
                    <ul class="footer-links">
                        <li><a href="#" class="footer-link">Contact us </a></li>
                        <li><a href="#" class="footer-link">Terms of Use</a></li>
                        <li><a href="#" class="footer-link">Report an Adverse Event</a></li>
                        <li><a href="#" class="footer-link">Website Privacy Policy</a></li>
                        <li><a href="#" class="footer-link">Cookies settings</a></li>
                        <li><a href="#" class="footer-link">Prescribing information </a></li>
                    </ul>
                </div>
            </div>
        </div>
    </footer>

    <!----------------------- JQUERY ----------------->
    <script src="asset/js/jquery-min.js"></script>

    <!-- BOOTSTRAP JS -->
    <script src="asset/js/bootstrap.bundle.min.js"></script>
    <!----------------------- OWL CAROUSEL ----------------->
    <script src="asset/js/owl.carousel.min.js"></script>
    <!-- script js -->
    <script src="asset/js/script.js"></script>
</body>

</html>